 MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, announced on January 7, 2021 a capital increase of 262,812 new shares of the Company to Lincoln Park Capital Fund, LLC LPC, a Chicago-based institutional investor. As a result, the Companys share capital is increased to 49,427,200.33 EUR and is represented by 14,132,832 shares. 